Variation in the BDNF Val66Met polymorphism and response to cognitive-behavior therapy in obsessive-compulsive disorder

Eur Psychiatry. 2012 Jul;27(5):386-90. doi: 10.1016/j.eurpsy.2011.09.005. Epub 2011 Dec 6.

Abstract

Background: Recent research suggests that the brain-derived neurotrophic factor (BDNF) may play a role in extinction learning. The goal of this study was to test whether variation in the BDNF Val66Met polymorphism is related to treatment response to exposure-based cognitive-behavior therapy (CBT), a form of extinction learning, in obsessive-compulsive disorder (OCD).

Methods: One hundred and six OCD patients from a specialized clinic, who underwent a standardized CBT treatment after partial or non-response to a 12-week pharmacological trial, were genotyped for the BDNF Val66Met and the relationship between genotype and treatment response was analyzed.

Results: Among 98 CBT completers, 36% of those carrying the BDNF Met allele were rated as CBT responders compared to 60% of nonMet allele carriers (P=0.027). When analyzing the different obsessive-compulsive symptom dimensions, in patients with contamination/cleaning symptoms, the Met allele was associated with a significantly worse CBT response (P<0.0001) and a lower obsessions severity decrease from pre- to posttreatment (P=0.046).

Conclusion: Genetic variation in BDNF may be associated with treatment response in exposure-based CBT in OCD, especially in those patients exhibiting contamination/cleaning symptoms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alleles
  • Brain-Derived Neurotrophic Factor / genetics*
  • Cognitive Behavioral Therapy*
  • Female
  • Gene-Environment Interaction
  • Genetic Variation*
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Obsessive-Compulsive Disorder / genetics*
  • Obsessive-Compulsive Disorder / psychology
  • Obsessive-Compulsive Disorder / therapy*
  • Polymorphism, Single Nucleotide*
  • Treatment Outcome

Substances

  • Brain-Derived Neurotrophic Factor